Skip to content

Study · Randomized controlled trial · n = 260 · 2016

1 result

Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial.

Eaton AA, Gonen M, Karanicolas P, Jarnagin WR, D'Angelica MI, DeMatteo R, Kingham TP, Allen PJ

Annals of surgical oncology19 Jan 2016Cited by 37 (Europe PMC)

PMID26786091 (opens in a new tab)PMCIDPMC4891251 (opens in a new tab)DOI10.1245/s10434-015-5077-z (opens in a new tab)PepBankPUB-26786091
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In pancreatectomy patients, quality-of-life measures showed no major differences between pasireotide and placebo groups.

    In plain wordsIn pancreatectomy patients, quality-of-life measures showed no major differences between pasireotide and placebo.

    Peptide
    Pasireotide
    Outcome
    Direction not reportedQuality of life
    Study

    n = 260

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No major differences were observed between the pasireotide and placebo groups.
    4 context sentences
    Summary · context
    This secondary analysis aimed to describe quality of life (QoL) before and after resection, to characterize the impact of PC on QoL, and to assess whether pasireotide improves QoL.
    Summary · context
    A randomized, double-blind, placebo-controlled trial of preoperative pasireotide in patients undergoing pancreatectomy was conducted.
    Summary · context
    Participants completed the European Organization for Research and Treatment of Cancer (EORTC) C30 and PAN26 modules preoperatively and on postoperative days 14 and 60.
    Summary · context
    All questionnaires were completed by 87 % (260/300) of the patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.